Advanced search

Diquafosol tetrasodium: a novel dry eye therapy.

Kelly K Nichols, Ben Yerxa, Donald J Kellerman

Journal: Expert opinion on investigational drugs 2004;13(1):47-54

PMID: 14680452

Full Text on Atypon View on PubMed

Abstract

The ophthalmic formulation of diquafosol tetrasodium (INS365), a P2Y2 receptor agonist, is targeted to treat dry eye disease through rehydration of the ocular surface. Existing pharmacological therapies for dry eye disease are limited, therefore, approval of this medication is anticipated. This review summarises key findings during development and in clinical trials including clinical effectiveness and safety. The relevance of P2Y2 receptor technology to dry eye disease and the disease process is discussed.

Address: The Ohio State University, College of Optometry, Columbus, OH, USA.
DOI: 10.1517/13543784.13.1.47

Link outs

Free resources

Medical:

Other Literature Sources:

Subscription / membership required

Full Text Sources:

MeSH Terms: Biological Availability, Clinical Trials as Topic, Dry Eye Syndromes, Humans, Ophthalmic Solutions, Polyphosphates, Purinergic P2 Receptor Agonists, Treatment Outcome, Uracil Nucleotides
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.